Table 1.

Trial Level Results of Meta-analysis

Variable	No. of Trials	No. of Patients	Effect Size (95% CI), mm Hg	P Value	I2, %	Between-Group P Value
Systolic Blood Pressure
Overall	46	4541	0.0 (−0.8 to 0.8)	.97	21	NA
Mean baseline SBP >140 mm Hg	16	1361	−0.7 (−3.2 to 1.7)	.55	38	.54
Mean baseline SBP ≤140 mm Hg	30	3180	0.1 (−0.6 to 0.9)	.77	11
Vitamin D2 and D3 supplements	38	4058	0.0 (−0.9 to 0.9)	.97	26	NA
1-α-Hydroxylated vitamin D derivatives	5	191	−1.6 (−6.3 to 7.1)	.50	4	.64
Paricalcitol	3	292	1.4 (−3.3 to 6.1)	.56	0	.57
Mean baseline 25OHD level ≤20 ng/mL	27	2555	−0.7 (−2.2 to 0.7)	.31	38	.31
Mean baseline 25OHD level >20 ng/mL	13	1723	0.1 (−0.4 to 0.6)	.75	0
Daily dosing	16	1522	−0.7 (−2.5 to 1.0)	.41	24	NA
Weekly/fortnightly dosing	8	1303	1.3 (−0.1 to 2.6)	.07	0	.07
Monthly or less frequent dosing	14	1216	−0.2 (−1.6 to 1.2)	.76	28	.66
Diastolic Blood Pressure
Overall	45	4434	−0.1 (−0.6 to 0.5)	.84	20	NA
Mean baseline SBP >140 mm Hg	14	1074	−0.4 (−2.1 to 1.3)	.61	55	.65
Mean baseline SBP ≤140 mm Hg	30	3180	0.0 (−0.4 to 0.3)	.85	0
Vitamins D2 and D3 supplements	37	3951	0.1 (−0.3 to 0.5)	.65	4	NA
1-α-Hydroxylated vitamin D derivatives	5	191	−3.5 (−6.8 to −0.1)	.04	54	.04
Paricalcitol	2	112	−1.0 (−3.9 to 1.9)	.50	0	.46
Mean baseline 25OHD level ≤20 ng/mL	26	2375	0.2 (−0.5 to 1.0)	.54	17	.50
Mean baseline 25OHD level >20 ng/mL	12	1616	−0.1 (−0.5 to 0.4)	.69	0
Daily dosing	16	1466	−0.5 (−1.5 to 0.4)	.26	23	NA
Weekly/fortnightly dosing	8	1303	0.6 (−0.4 to 1.5)	.23	0	.11
Monthly or less frequent dosing	14	1213	0.0 (−0.4 to 0.5)	.84	0	.35

Abbreviations: SBP, systolic blood pressure; NA, not applicable; 25OHD, 25-hydroxyvitamin D.

SI conversion factor: To convert 25OHD to nanomoles per liter, multiply by 2.496.